| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Enpp-1-IN-16 is designed to inhibit ENPP1. This target is involved in nucleotide metabolism and is a negative regulator of the cGAS-STING immune pathway, as well as a key enzyme in the generation of pyrophosphate, which is a regulator of tissue calcification. By inhibiting ENPP1, Enpp-1-IN-16 has the potential to modulate these pathways.
|
|---|---|
| ln Vitro |
The primary evidence for the activity of Enpp-1-IN-16 is its ability to inhibit ENPP1. While specific IC50 data is not provided in the datasheet, its classification as an ENPP1 inhibitor implies it was validated in a biochemical enzyme assay. In cellular contexts, its activity would be inferred from downstream effects such as increased STING signaling or decreased extracellular pyrophosphate levels.
|
| ln Vivo |
In vivo data for Enpp-1-IN-16 is not detailed. However, its potential for studying diseases like cancer, insulin resistance/type II diabetes, and chondrocalcinosis/osteoarthritis suggests it is being evaluated in animal models for these conditions, where it may show therapeutic effects through modulation of ENPP1 activity.
|
| Enzyme Assay |
To confirm the inhibition of ENPP1, a typical non-cellular protocol is used. A standard assay involves incubating varying concentrations of Enpp-1-IN-16 with recombinant human ENPP1 protein in a reaction buffer. A substrate, such as thymidine 5'-monophosphate p-nitrophenyl ester (p-Nph-5'-TMP), is added. The reaction is initiated and after a set time, the released p-nitrophenol is measured by absorbance at 405 nm to calculate the IC50.
|
| Cell Assay |
No specific cell-based experimental procedure for Enpp-1-IN-16 is standardly reported. Given the role of ENPP1 in cancer, cellular assays would likely involve treating cancer cell lines with high ENPP1 expression with the compound, then measuring markers of cell proliferation, viability, or signaling pathways like the cGAS-STING pathway.
|
| Animal Protocol |
No specific in vivo animal protocol for Enpp-1-IN-16 is provided in these documents. For studying its potential in osteoarthritis or insulin resistance, a mouse model on a high-fat diet would be used. Enpp-1-IN-16 would be administered, and parameters like blood glucose, insulin sensitivity, and joint inflammation would be measured.
|
| ADME/Pharmacokinetics |
No specific pharmacokinetic parameters are available for Enpp-1-IN-16. For a small-molecule ENPP1 inhibitor intended for in vivo studies, typical parameters of interest would include its half-life (t1/2), oral bioavailability, and plasma protein binding. These data are crucial for designing effective dosing regimens in animal models.
|
| Toxicity/Toxicokinetics |
Toxicological data for Enpp-1-IN-16 is not available. As a research compound, standard safety assessments would be performed in the context of its intended use. Because ENPP1 is also involved in tissue calcification and insulin signaling, toxicity studies would need to monitor for effects on bone metabolism and glucose homeostasis.
|
| References | |
| Additional Infomation |
Enpp-1-IN-16 is a versatile research tool because ENPP1 is implicated in a diverse range of diseases. Beyond its role in cancer immunity via the STING pathway, ENPP1 is also a major player in the generation of inorganic pyrophosphate (PPi). PPi is a potent inhibitor of hydroxyapatite crystal formation, and mutations in ENPP1 can lead to disorders like generalized arterial calcification of infancy (GACI). This makes Enpp-1-IN-16 a potential tool for studying calcification disorders.
|
| Exact Mass |
428.242
|
|---|---|
| CAS # |
2289739-47-3
|
| PubChem CID |
137536906
|
| Appearance |
Off-white to light yellow solid powder
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
31
|
| Complexity |
632
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(C)OC(=O)N1CCC2(C1)CCN(CC2)C3=NC=NC4=CC(=C(C=C43)OC)OC
|
| InChi Key |
USKNLBGKOOFYMG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H32N4O4/c1-22(2,3)31-21(28)27-11-8-23(14-27)6-9-26(10-7-23)20-16-12-18(29-4)19(30-5)13-17(16)24-15-25-20/h12-13,15H,6-11,14H2,1-5H3
|
| Chemical Name |
tert-butyl 8-(6,7-dimethoxyquinazolin-4-yl)-2,8-diazaspiro[4.5]decane-2-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 2 mg/mL (4.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
